Unfortunately, we don't support Internet Explorer anymore as it has been replaced by Microsoft Edge. Please try using Edge or an alternative modern browser for the best experience.
Unfortunately, we don't support Internet Explorer anymore as it has been replaced by Microsoft Edge. Please try using Edge or an alternative modern browser for the best experience.
Learn
Share
Network
Benefit
Delivering Affordable Innovation Through Global Partnerships
Chief Executive Officer
ProFound Therapeutics
John Lepore, MD, joins ProFound after 17 years at GSK where he had extensive experience leading large international R&D organizations across diverse therapeutic areas. Dr. Lepore was most recently Senior Vice President, Head of Research at GSK where he led a large organization of scientists and physicians focused on leveraging the science of immunology, human genetics and genomics, and advanced technologies to identify novel drug targets, discover new therapeutic molecules, and demonstrate proof of mechanism in clinical studies.
Dr. Lepore joined GSK in 2006 and has held roles of increasing responsibility including VP of Clinical Pharmacology and Discovery Medicine, VP and Head of the Heart Failure Discovery Performance Unit, SVP and Head of the Metabolic Pathways and Cardiovascular Therapeutic Area Unit, and SVP R&D Pipeline responsible for end-to-end R&D activities across multiple therapeutic areas. He was also Interim Head of Business Development and played a key role in multiple preclinical and clinical deals to augment the GSK pipeline.
Before joining GSK, Dr. Lepore was on the faculty of the Cardiovascular Medicine Division of the Department of Medicine at the University of Pennsylvania, where his lab investigated the transcriptional regulation of cardiovascular development and he was attending physician on the academic cardiology service.
Dr. Lepore received his B.S. in Biology from the University of Scranton and his medical degree from Harvard Medical School where he was a Howard Hughes Medical Institute Research Scholar. He subsequently trained in internal medicine and cardiology and served as Medical Chief Resident at Massachusetts General Hospital, with post-doctoral training at the Harvard School of Public Health.
Dr. Lepore has been on the Board of Directors of ViiV Healthcare, the Altius Institute, and the Biotechnology Innovation Organization (BIO), the Scientific Advisory Boards of Medicxi Ventures and Hatteras Ventures, and the Innovation Growth Board of Mass General Brigham. At GSK, he chaired the Research Review Board and Research Investment Board responsible for capital allocation and project prioritization.